| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697521 | Cancer Treatment and Research Communications | 2017 | 6 Pages |
Abstract
We found no evidence for the activity of dovitinib in patients who had recently progressed on anti-VEGF therapy and toxicities were significant. In tumors progressing despite anti-VEGF therapy, a multitude of pro-angiogenic mediators are expressed, including members of the FGF pathway.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Thomas J. Semrad, Edward J. Kim, Michael S. Tanaka, Jacob Sands, Chris Roberts, Rebekah A. Burich, Yu Li, David R. Gandara, Primo Jr., Philip C. Mack,